Dr.PeteFamMed said:CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 7.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…
NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.
Compare to established therapies:
| Intervention | NNT | Timeframe |
|---|---|---|
| Semaglutide (MACE) | 67 | 3.3 years |
| Statins primary prevention (MI) | ~100 | 5 years |
| Aspirin secondary prevention | ~77 | 2 years |
These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.
A narrower follow-up, since the general answer is now clear:
Was that from a primary source or from a summary of one?
SleepDoc_PDX said:NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
Pushing back on SleepDoc_PDX here. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemSleepDoc_PDX said:NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
SleepDoc_PDX has the substance of this right. The condition it depends on is worth stating. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.
SleepDoc_PDX said:NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.